Skip to content

Integrated [68Ga]Ga-FAPI-7ND PET/CT and stromal profiling of immunocompetent syngeneic tumor models for FAP-targeted radionuclide therapy.

Oct 2026 · Nuclear Medicine and Biology · Vol 162-163, pp. 109844 · 0 citations · 48 references
Medicine

TL;DR

In 4 T1 tumors, [177Lu]Lu-FAPI-7ND showed antitumor activity accompanied by immune microenvironmental alterations, supporting integrated model selection for immunocompetent FAP-RNT studies.

Abstract

Background

Most preclinical studies of fibroblast activation protein (FAP)-targeted radionuclide therapy (FAP-RNT) use immunodeficient xenografts, limiting evaluation within an intact immune microenvironment. This study aimed to characterized FAP-associated stromal and FAP inhibitor (FAPI) imaging phenotypes across immunocompetent syngeneic tumors and explored FAP-RNT effects in a representative model.

Methods

Four syngeneic models (MC38, PAN02, LLC1, and 4 T1) were assessed using [68Ga]Ga-FAPI-7ND PET/CT, Western blotting, immunohistochemistry, and multiplex immunofluorescence for tracer uptake, FAP and α-SMA expression, and co-expression. Based on these findings, 4 T1-bearing mice underwent an exploratory therapeutic evaluation with saline or a single intravenous injection of [177Lu]Lu-FAPI-7ND. Tumor volume and body weight were measured every 2 days, and tumors were harvested on day 7 for histological and molecular analyses.

Results

All models showed higher tumor uptake than contralateral muscle (all P < 0.05), with significant inter-model differences (P = 0.005) but comparable tumor-to-background ratios (P = 0.369). PAN02 had the highest uptake and enriched FAP+α-SMA+ stroma, whereas 4 T1 combined relatively high uptake with pronounced α-SMA-associated stromal activation. Because FAP-RNT response may reflect both tracer accumulation and stromal state, 4 T1 was selected for exploratory treatment. [177Lu]Lu-FAPI-7ND inhibited tumor growth (P < 0.0001) without significant body-weight loss. Treatment reduced CD8+ T-cell (P < 0.0001) and FOXP3+ regulatory T-cell densities (P = 0.012), did not alter their ratio (P = 0.537), and increased CD206-associated macrophage features (P < 0.05).

Conclusion

Syngeneic models exhibit distinct FAP-associated stromal and imaging phenotypes. In 4 T1 tumors, [177Lu]Lu-FAPI-7ND showed antitumor activity accompanied by immune microenvironmental alterations, supporting integrated model selection for immunocompetent FAP-RNT studies.

View source

Similar papers

Oct 2026

Design and Biological Evaluation of FAP-Man, a Mannosylated FAP-Targeted Radioglycopeptide for Tumor Imaging and Radionuclide Therapy.

Fibroblast activation protein (FAP) is an attractive target for radiotheranostic development because of its abundant expression in tumor-associated fibroblasts and limited distribution in normal tissues. Here, we developed FAP-Man, a mannosylated FAP-targeted radioglycopeptide based on the FAP-2286 scaffold, to optimiz...

Miao-Miao Song, En-Tao Liu, Rui Cao et al. · 0 citations
Open access Sep 2026

[64/67Cu]-FAP theranostics in combination with immunotherapy in a preclinical model of TNBC

The authors can noninvasively target and predict response to FAP radiolabeled with elementally paired theranostic probe, [64/67Cu]-FAP2287 in TNBC and can guide personalized approaches to improve treatment efficacy.

Sharmila Sridhar, Volkan Tekin, Addison Hunt et al. · 0 citations
Open access Oct 2026

Preclinical Evaluation of 177Lu-Labeled PSMA and FAP Bispecific Radioligand for Prostate Cancer

Background/Objectives: During prostate cancer progression, downregulation or loss of prostate-specific membrane antigen (PSMA) expression, together with interlesional heterogeneity, may limit the efficacy of PSMA-targeted radioligand therapy. Fibroblast activation protein (FAP), expressed mainly by activated cancer-ass...

R. Xue, Ya-Chao Liu, Xin-Lin Wang et al. · 0 citations
Oct 2026

FAP-targeted [177Lu]Lu-FAP-2286 radioligand therapy synergizes with the STING agonist diABZI to enhance antitumor immunity in lung cancer.

This combination reshapes the tumor immune microenvironment via enhanced CD8+ T-cell infiltration and IFN-β-mediated immune activation and IFN-β-mediated immune activation, offering a translatable strategy for patients with advanced FAP-expressing lung cancer.

Jia-Hao Xie, Yi-Jin Zou, Da-Zhi Shi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.